

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
12 December 2024 (12.12.2024)



(10) International Publication Number
WO 2024/254111 A1

(51) International Patent Classification:
C07C 225/20 (2006.01) A61P 25/00 (2006.01)

(21) International Application Number:
PCT/US2024/032487

(22) International Filing Date:
05 June 2024 (05.06.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/471,091 05 June 2023 (05.06.2023) US
63/580,073 01 September 2023 (01.09.2023) US

(71) Applicant: **GILGAMESH PHARMACEUTICALS, INC.** [US/US]; 113 University Place, Suite 1019, New York, New York 10003 (US).

(72) Inventors: **LEONG, William**; c/o Gilgamesh Pharmaceuticals, Inc., 113 University Place, Suite 1019, New York, New York 10003 (US). **JOU, Yow-Rong Catrina**; c/o Gilgamesh Pharmaceuticals, Inc., 113 University Place, Suite 1019, New York, New York 10003 (US). **CHATURVEDI, Kaushalendra**; c/o Gilgamesh Pharmaceuticals, Inc., 113 University Place, Suite 1019, New York, New York 10003 (US). **GAO, Qi**; c/o Gilgamesh Pharmaceuticals, Inc., 113 University Place, Suite 1019, New York, New York 10003 (US).

(74) Agent: **GROLZ, Edward**; Scully, Scott, Murphy & Presser, 400 Garden City Plaza, Suite 300, Garden City, New York 11530 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— with international search report (Art. 21(3))

(54) Title: CRYSTALLINE SALTS OF 2-PHENYL-2-AMINOCYCLOHEXAN-1-ONE DERIVATIVES

(57) Abstract: The present disclosure relates to various crystalline salts of (R)-2-(4-fluorophenyl)-2-(methlamino)cyclohexan-1-one, which are useful for treating psychiatric disorders, including treating mood disorders. These salts include the hydrochloride salts, sulfate salts, p-toluenesulfonate salts, methanesulfonate salts, maleate salts, phosphate salts, tartrate salts, fumarate salts, citrate salts, glycolate salts, malate salts, and hippurate salts thereof.

WO 2024/254111 A1